CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

DelveInsight's CDK 7 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical trials of CDK inhibitors such as Samuraciclib and Q901, and the growing number of these inhibitors ...